Deaths Prompt Warnings On Rituxan

Law360, New York (December 19, 2006, 12:00 AM EST) -- The U.S. Food and Drug Administration and the drug makers are warning the public that two patients who have taken non-Hodgkins lymphoma and rheumatoid arthritis drug Rituxan have died from a rare nervous system disease.

The FDA said Monday that the patients were taking the drug for systemic lupus erythematosus and developed progressive multifocal leukoencephalopathy or PML, which is a fatal viral infection of the central nervous system. The patients reported the infection as late as a year after their last doses of the drug....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.